File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.virol.2018.09.007
- Scopus: eid_2-s2.0-85053722283
- PMID: 30248524
- WOS: WOS:000452938600008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection
Title | Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection |
---|---|
Authors | |
Keywords | Heterosubtypic immunity Influenza Universal vaccine |
Issue Date | 2018 |
Publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviro |
Citation | Virology, 2018, v. 525, p. 73-82 How to Cite? |
Abstract | The limited protection of current commerical vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations. Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses. |
Persistent Identifier | http://hdl.handle.net/10722/261234 |
ISSN | 2021 Impact Factor: 3.513 2020 SCImago Journal Rankings: 1.389 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan, L | - |
dc.contributor.author | Li, OTW | - |
dc.contributor.author | Poh, CM | - |
dc.contributor.author | Perera, RAPM | - |
dc.contributor.author | Doak, SA | - |
dc.contributor.author | Peiris, JSM | - |
dc.contributor.author | Poon, LML | - |
dc.date.accessioned | 2018-09-14T08:54:46Z | - |
dc.date.available | 2018-09-14T08:54:46Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Virology, 2018, v. 525, p. 73-82 | - |
dc.identifier.issn | 0042-6822 | - |
dc.identifier.uri | http://hdl.handle.net/10722/261234 | - |
dc.description.abstract | The limited protection of current commerical vaccines necessitates the investigation of novel vaccine strategies for unpredictable outbreaks. To investigate the feasibility of using vaccines derived from Group 1 influenza A virus to induce broadly cross-reactive immune responses against multiple influenza subtypes, we tested a panel of sequential 4-dose immunization regimens in mice. Mice were treated with inactivated (seasonal H1N1, pandemic H1N1 and H5N1) and vaccinia virus-based H5N1 live-attenuated vaccines in different combinations. Mice were then challenged by viruses of either Group 1 (H1N1) or Group 2 (H3N2, H7N7) influenza virus. All studied sequential 4-dose vaccinations could induce some degrees of heterosubtypic protection in mice. Amongst all these regimens, the combined use of inactivated and live-attenuated vaccines could achieve the best heterologous protection. These results highlight the synergistic effect of combining different vaccine platforms to enhance heterosubtypic protection against influenza viruses. | - |
dc.language | eng | - |
dc.publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviro | - |
dc.relation.ispartof | Virology | - |
dc.subject | Heterosubtypic immunity | - |
dc.subject | Influenza | - |
dc.subject | Universal vaccine | - |
dc.title | Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection | - |
dc.type | Article | - |
dc.identifier.email | Yan, L: ylmeng@hku.hk | - |
dc.identifier.email | Poh, CM: pohcm@hku.hk | - |
dc.identifier.email | Perera, RAPM: mahenp@hku.hk | - |
dc.identifier.email | Doak, SA: sophiev@hku.hk | - |
dc.identifier.email | Peiris, JSM: malik@hkucc.hku.hk | - |
dc.identifier.email | Poon, LML: llmpoon@hkucc.hku.hk | - |
dc.identifier.authority | Doak, SA=rp02141 | - |
dc.identifier.authority | Peiris, JSM=rp00410 | - |
dc.identifier.authority | Poon, LML=rp00484 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.virol.2018.09.007 | - |
dc.identifier.pmid | 30248524 | - |
dc.identifier.scopus | eid_2-s2.0-85053722283 | - |
dc.identifier.hkuros | 291639 | - |
dc.identifier.hkuros | 293645 | - |
dc.identifier.volume | 525 | - |
dc.identifier.spage | 73 | - |
dc.identifier.epage | 82 | - |
dc.identifier.isi | WOS:000452938600008 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0042-6822 | - |